Neurocrine Improves Financial Position by Partnering with Abbott and Boehringer Ingelheim
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 13 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1369 ISSN: 1756-7874
Section: Joint Venture
Fulltext:
Abstract
Neurocrine Biosciences announced two deals in the space of 24 hours with Abbott, for its experimental drug elagolix, and with Boehringer Ingelheim, to discover and develop small molecule G-protein coupled receptor 119 (GPR 119) agonists to treat type 2 diabetes and other indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS